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Abstract
The gut-brain axis is a bidirectional communication network functionally linking the gut and the central nervous system (CNS).
Based on this, the rational manipulation of intestinal microbiota represents a novel attractive therapeutic strategy for the treatment
of CNS-associated disorders. In this study, we explored the properties of a probiotic formulation (namely SLAB51) in
counteracting brain oxidative damages associated with Alzheimer’s disease (AD). Specifically, transgenic AD mice (3xTg-
AD) were treated with SLAB51 and the effects on protein oxidation, neuronal antioxidant defence and repair systems were
monitored, with the particular focus on the role of SIRT1-related pathways. We demonstrated that SLAB51 markedly reduced
oxidative stress in AD mice brain by activating SIRT1-dependent mechanisms, thus representing a promising therapeutic
adjuvant in AD treatment.
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Introduction
Alzheimer’s disease (AD) is a devastating form of dementia
characterized by profound brain alterations and behavioural dis-
orders. The histopathological hallmark of AD is the progressive
accumulation of abnormal amyloid-β (Aβ) peptides and
hyperphosphorylated tau protein in the brain of ageing subjects,
as amyloid plaques and neurofibrillary tangles, respectively. In
details, Aβ peptides are produced by proteolytic cleavage of the
transmembrane amyloid precursor protein (APP), whereas tau is
a brain-specific, axon-enriched protein normally associated with
microtubules that loses its affinity for these structures upon phos-
phorylation [1]. Oxidative stress represents the mechanism
through which Aβ neurotoxic peptides and tau protein mediate
neurodegenerative processes and cause impaired synaptic plas-
ticity, neuro-inflammation, neuronal and synaptic loss and
neurotransmitter imbalance in AD [2] that ultimately correlates
with the classical behavioural symptoms of AD [1].
Growing evidence supports the relevant role of oxidative
stress in the onset and progression of AD: inadequate antiox-
idant defence systems, high O2 consumption, the presence of
excitotoxic amino acids and high iron content promote the
production of reactive oxygen and nitrogen species (ROS
and RNS, respectively) in the brain [3, 4]. ROS and RNS
are extremely unstable species that easily react with proteins,
lipids, carbohydrates and nucleic acids, causing oxidative
modifications that finally result in cellular dysfunctions [5,
6]. Comparative redox proteomic analysis of cerebrospinal
fluid samples from mild cognitive impairment (MCI), the ear-
liest clinical phase of AD, AD and control individuals identi-
fied specific oxidatively modified proteins early in the pro-
gression of AD [7]. Higher levels of protein carbonyls were
detected in the hippocampus of 3xTg-AD mice as early as
3 months of age [8]. High levels of 4-hydroxy-2-nonenal (4-
HNE), an extremely reactive aldehyde produced by mem-
brane lipid peroxidation, were observed in the brain of MCI
patients compared to controls [9, 10]. Interestingly, HNE was
shown to bind both nicastrin, a component of the γ-secretase
complex, and BACE, a β-secretase enzyme, differentially af-
fecting their activity and thus altering APP processing [11].
Several authors reported on the occurrence of oxidative
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modifications to DNA (both nuclear and mitochondrial) [12]
and RNA in the brain of AD subjects by detecting the levels of
8-hydroxy-2′-deoxyguanosine (8-oxodG), a marker of nucleic
acid oxidation [13–15]. In addition, the increased oxidative
profile has been often associated with a decrease both in the
activity of antioxidant enzyme systems, including superoxide
dismutase (SOD), catalase (CAT), glutathione peroxidase
(GPx) and 8-oxoguanine DNA glycosylase-1 (OGG1) and
in the levels of antioxidant molecules, among these glutathi-
one [16–18].
Sirtuin-1 (SIRT1) is a NAD+-dependent protein
deacetylase with established neuroprotective action, which is
able to lower ROS levels and promote cell survival [19, 20]. In
particular, SIRT1 protects cell from oxidative stress by mod-
ulating the transcription factors p53 and the forkhead O
(FOXO) family [20–22]. Other mechanisms through which
SIRT1 inhibits apoptosis include the deacetylation of Ku70,
poly(ADP-ribose) polymerase-1 (PARP), Smad7 and HSF1
[19]. Interestingly, the activation of SIRT1-coupled retinoic
acid receptor-β (RARβ) attenuated Aβ production in N2a
cells expressing human APP Swedish mutation by increasing
the activity of a disintegrin and metalloproteinase 10
(ADAM10)/α-secretase, suggesting a protective role for
SIRT1 in AD [23].
In recent years, an increasing number of studies has been
focusing on the role of the gut microbiota in disorders associated
with the central nervous system (CNS), with special interest in
the modulation of the gut-brain axis, a bidirectional system that
integrates the gut and CNS activities [24, 25]. For this reason, the
use of probiotics to modulate gut microbiota has been proposed
for its positive effects in the prevention and treatment of allergies,
gastrointestinal and urogenital tract infections, inflammatory dis-
ease, cystic fibrosis, certain type of cancers and, recently, also
some CNS-associated disturbs [26]. Interestingly, the rational
manipulation of intestinal microbiota in rats treated with
VSL#3, a probiotic mixture containing eight bacterial strains,
attenuated the age-related deficit in long-term potentiation and
modulated the expression of several genes in the brain [27]. In a
similar context, we recently demonstrated that 3xTg-AD mice
administered with a novel formulation of lactic acid bacteria and
bifidobacteria, namely SLAB51, exhibited evidence of attenua-
tion of cognitive decline, reduction in Aβ aggregates and brain
damages and partial restoration of impaired neuronal proteolytic
pathways [28].
In this study, we further explored the role of SLAB51 in
counteracting AD-associated symptoms with the specific aim
of evaluating its ability to modulate brain oxidative status. For
this purpose, 3xTg-ADmice were administered with SLAB51
and the effects on macromolecule oxidation, neuronal antiox-
idant defence and repair systems were assessed, with the focus
on the role of SIRT1 pathways. Our data demonstrated that
SLAB51 markedly reduces oxidative stress in AD mice brain
by activating SIRT1-dependent mechanisms and therefore
may be considered as a potential therapeutic adjuvant in AD
treatment.
Material and Methods
Reagents and Chemicals
SLAB51 formulation was provided byMendes S.A. (Lugano,
Switzerland). PVDFmembranes forWestern blotting analyses
were purchased from Millipore (Milano, Italy). Proteins
immobilized on films were detected with the enhanced chemi-
luminescence (ECL) system (Amersham Pharmacia Biotech,
Milano, Italy). SIRT1 (Merck Millipore, Darmstadt,
Germany) and acetyl-p53(Lys379) antibodies were obtained
from Cell Signaling Technology (Danvers, Massachusetts,
USA). All other antibodies were from Santa Cruz
Biotechnology (Heidelberg, Germany). The molecular
probes’ protein molecular weight standards (6–205 kDa)
(Sigma Aldrich, Italy) were used for molar mass calibration
(it includes myosin 205 kDa, β-galactosidase 116 kDa, phos-
phorylase b 97 kDa, fructose-6-phosphate kinase 80 kDa, al-
bumin 66 kDa, glutamic dehydrogenase 55 kDa, ovalbumin
45 kDa, carbonic anhydrase 30 kDa, trypsin inhibitor 21 kDa,
lysozyme 14 kDa, aprotinin 6.5 kDa). Superoxide dismutase
assay kit, reagents for antioxidant enzyme activities and pro-
tease inhibitors N-p-tosyl-phenylalanyl chloromethyl ketone
(TPCK) and 4-(2-aminoethyl) benzenesulfonyl fluoride hy-
drochloride (AEBSF or Pefabloc) were from Sigma-Aldrich
S.r.L. (Milano, Italy).
Experimental Animals
The triple-transgenic mouse model of AD, B6;129-
Psen1tm1Mpm Tg (APPSwe,tauP301L)1Lfa/J (namely,
3xTg-AD) and control wild-type animals were purchased
from the Jackson Laboratory (Bar Harbor, Maine, USA).
3xTg-AD mice were previously characterized and represent
a reliable model of human AD patients. In this model, Aβ
intracellular immunoreactivity can be detected in some brain
regions as early as 3 to 4 months of age [29]. Experiments
were conducted using 8-week-old male mice (weight 15–
25 g) in accordance with the guidelines of the European
Communities Council (86/609/ECC) for the care and use of
laboratory animals. Mice were housed in plastic (Makrolon)
cages (four animals per cage) in a temperature-controlled
room (21 ± 5 °C) and 60% humidity on 12 h light/dark
inverted cycle (light was switched on at 8:00 P.M.) and main-
tained on laboratory diet (Mucedula, Italy) with water ad
libitum. All appropriate measures were taken tominimize pain
and discomfort in experimental animals.
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SLAB51 Administration
Eight-week-old male 3xTg-AD mice (n = 64) were divided in
two groups: one was administered for 16 weeks with SLAB51
in water, and the control group was administered with water.
Simultaneously, 64 age-matched wild-type (wt) mice were
divided into wt control and wt-treated groups. SLAB51 is a
formulation made of nine live bacterial strains (Streptococcus
thermophilus, bifidobacteria (Bifidobacterium longum,
B. breve, B. infantis), lactobacilli (Lactobacillus acidophilus,
L. plantarum, L. paracasei, L. delbrueckii subsp. bulgaricus,
L. brevis)). The dosage (200bn bacteria/Kg/day) was deter-
mined using the body surface area normalization [30]. The
body weight was measured every 2 weeks before starting the
treatment, then several times a week during the treatment to
ensure single-housed animals received the proper intake of the
experimental food. Preliminary studies were performed to
evaluate both viability and stability of the probiotic formula-
tion upon solubilisation in water at 21 ± 5 °C. The percentage
of vital bacteria was determined by fluorescence microscopy,
which revealed that 88% of the strains survived after 30 h
under the abovementioned conditions. Thus, the drinking so-
lution was changed every day replacing the bottles with fresh
solutions. Mice were sacrificed for biochemical analyses at
12, 18 and 24 weeks of age, and the brains were properly
stored at − 80 °C.
Preparation of Brain Extracts
Mouse brain tissues were homogenized in 50 mM Tris buffer,
150 mM KCl, 2 mM EDTA, pH 7.5 (1:5 weight:volume of
buffer). Homogenates were immediately centrifuged at
13,000×g for 20 min at 4 °C, and supernatant and pellet frac-
tions were collected. Protein content was determined by the
Bradford method [31] using bovine serum albumin (BSA) as
standard.
Sirtuin-1 Activity
SIRT1 activity was determined using the fluorescent
SIRT1 substrate (Lys379/382 residues of p53), Arg-
His-Lys-Lys-(ɛ-acetyl)-AMC (Cayman, Vinci-Biochem,
Italy). The assay was performed by incubating the sub-
strate at a final concentration of 125 μM, brain homog-
enates (30 μg of total protein content) and 3 mM NAD+
in the assay buffer (50 mM Tris-HCl, pH 8.0, contain-
ing 137 mM sodium chloride, 2.7 mM KCl and 1 mM
MgCl2). Upon 1 h of incubation at 37 °C, the
deacetylated product was cleaved by trypsin [32] and
the fluorescence of the released AMC was recorded on
a Spectramax Gemini XPS microplate reader (λexc
365 nm, λem 449 nm).
Analysis of RARβ Acetylation
RARβwas immunoprecipitated from brain homogenates, and
acetylated lysines were immunodetected. In detail, aliquots of
brain homogenates were incubated with agarose-conjugated
protein A immobilized on Sepharose CL-4B (Sigma-Aldrich
S.r.L., Milano, Italy), followed by SDS-PAGE and immuno-
blotting. After reconstituting the agarose-conjugated protein A
in deionized water, it was washed in washing buffer (Tris
50 mM, NaCl 150 mM, BSA 0.1%, pH 8) and centrifuged
at 12,000×g for 10 s at room temperature. The supernatant
was discarded and the agarose conjugate was re-suspended
in washing buffer and finally aliquoted in several 100-μL
fractions that were added with 2 μg of the primary antibody;
the tubes were incubated in a shaker for 60 min at room tem-
perature and then centrifuged at 3000×g for 2 min at 4 °C.
Again, supernatants were discarded, washing steps with 1 mL
of washing buffer were performed and 500 μg of total protein
brain homogenates were added to each tube. After overnight
incubation in a rotating mixer at 4 °C, centrifugation,
discarding and washing steps were performed, to obtain the
pellets to be analysed by SDS-PAGE. Pellets were suspended
in 40 μL Laemmli sample buffer, heated at 95 °C for 5 min
and then centrifuged at 12,000×g for 30 s at room temperature.
Finally, 15 μL of the collected supernatant, containing
immunoprecipitated RARβ, were analysed by Western
blotting.
Redox Enzyme Activity Assays
Catalase (CAT) activity was determined in brain homoge-
nates following the Aebi protocol with minor modifications
[33]. Briefly, 20 μL of homogenate was added to 50 mM
potassium phosphate buffer (pH 7.0) and 9 mM H2O2. The
decrease in absorbance at 240 nm was monitored during the
first minute of incubation at 25 °C on a Varian Cary 1E spec-
trophotometer, and the Cary Win UV software was used to
analyse kinetic raw data. CAT activity was expressed as
μmol/min/mL of protein.
Superoxide dismutase (SOD) catalyses the dismutation of
the superoxide anion (O⋅−2 ) to H2O2 and O2. SOD activity was
measured in brains using the SOD Assay Kit-WST (Sigma-
Aldrich) following the manufacturer’s protocol, and the
change in absorbance at 440 nm was read on a Varian Cary
1E spectrophotometer.
Glutathione S-tranferase (GST) assay is based on the mon-
itoring of the increase in absorbance at 340 nm after conjuga-
tion of the thiol group of GSH to the 1-chloro-2,4-dinitroben-
zene (CDNB) substrate [34–36]. Briefly, 5 μL of brain ho-
mogenate were added to a mixture containing 0.2 M reduced
GSH, 0.2 M CDNB (previously dissolved in DMSO) and
potassium phosphate buffer (0.3 M, pH 6.5). The absorbance
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at 340 nm was monitored for 4 min (t = 25 °C). GST activity
was expressed as μmol/min/mL of protein.
Glutathione peroxidase (GPx) activity assay is based on
the reduction of tert-butyl hydroperoxide (TBH) under GSH
oxidation and subsequent reduction of GSSG by glutathione
reductase in the presence of NADPH. Briefly, 50 μL of the
homogenized sample were added to the mixture containing
50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 5 mM NADPH
and 42 mM reduced GSH. The decrease in NADPH absor-
bance measured at 340 nm during its oxidation to NADP+ is
related to GPx activity, since GPx is the rate limiting factor of
the coupled reactions [37, 38]. Reaction was monitored at
25 °C for 4 min. After 1 min of incubation, 30 mM H2O2
was added to start the reaction. The activity is expressed as
units of enzyme that catalyse the oxidation of one μmole of
NADPH per min.
Western Blotting Analyses
The levels of 3-nitrotyrosine (3-NT), 4-HNE, 8-oxodG,
OGG1, PARP1, p53 and acetyl-p53, catalase, SOD,
GST and GPx in brain homogenates were analysed by
Western blotting assays. In detail, for each time point,
brain homogenates (20 μg total protein) were subjected
to SDS-PAGE on 12% gels (10% for LC3) and
electroblotted onto PVDF membranes. Successively, up-
on incubation with specific antibodies, the immunoblot
detections were carried out with ECL Western blotting
analysis system. Molecular weight markers (6.5–
205 kDa) were included in each gel. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used to
check equal protein loading.
Oxyblot Analysis
Protein carbonyl groups were determined with the Oxyblot
kit (Appligene-Oncor, Strasbourg, France). Brain homoge-
nates (15 μg of total proteins) were incubated at room
temperature with 2,4-dinitrophenylhydrazine (DNPH) to
form 2,4-dinitrophenylhydrazone (DNP-hydrazone), ac-
cording to the manufacturer data sheet. Then, the DNPH-
derivatized samples were separated by SDS-PAGE and
electroblotted onto PVDF membranes. Transferred mem-
branes were sequentially incubated with an anti-DNP anti-
body and a secondary specific antibody. The detection was
performed with the ECL system [39]. In order to check
equal protein loading, reversible Ponceau staining was
used prior to incubation with the anti-DNP primary
Fig. 1 Effect of SLAB51 on
SIRT1 activity and expression.
SIRT1 activity (a) and expression
levels (b) measured in brain
homogenates of SLAB51-treated
and SLAB51-untreated wt (left)
and AD (right) mice. The enzyme
activity is expressed as fluores-
cent units (F.U.). The densito-
metric analyses obtained from
five separate blots and represen-
tative immunoblots are shown.
Equal protein loading was veri-
fied by using an anti-GAPDH
antibody. The detection was per-
formed with an ECLWestern
blotting analysis system.
Statistical significance compared
to untreated 8-week-old mice and
age-matched mice is indicated
with asterisks (*p < 0.05;
**p < 0.01; ***p < 0.001) and
hashtags (#p < 0.05; ##p < 0.01;
###p < 0.001), respectively
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antibody. Statistical significance was calculated consider-
ing the ratio between densitometric values of the oxyblot
bands (oxidation level) and those stained with Ponceau red
(protein content).
Statistical Analysis
Statistical analysis was performed with one-way ANOVA,
followed by the Bonferroni post hoc test using Sigma-stat
3.1 software (SPSS, Chicago, IL, USA). P values < 0.05 were
considered to be significant.
Results
SLAB51 Activates SIRT1 Pathway in AD Mice
We first explored the effects of SLAB51 on the SIRT1 path-
way. SIRT1 activity and expression remained unchanged in wt
mice throughout the experimentation, regardless of the treat-
ment. The only minor, still significant decrease was observed
only in SLAB51-treated wt mice at 18 weeks of age (Fig. 1,
left plots).
SIRT1 profile was markedly modified in transgenic mice
brains: specifically, SIRT1 activity progressively decreased
Fig. 2 Effect of SLAB51 on p53.
Acetylated p53 (a) and p53 (b)
levels measured in brain
homogenates of SLAB51-treated
and SLAB51-untreated wt (left)
and AD (right) mice. The densi-
tometric analyses obtained from
five separate blots and represen-
tative immunoblots are shown.
Equal protein loading was veri-
fied by using an anti-GAPDH
antibody. The detection was per-
formed with an ECLWestern
blotting analysis system.
Statistical significance compared
to untreated 8-week-old mice and
age-matched mice is indicated
with asterisks (*p < 0.05; **p <
0.01; ***p < 0.001) and hashtags
(#p < 0.05; ##p < 0.01;
###p < 0.001), respectively. (c)
Pairwise comparison of the ef-
fects of SLAB51 in Ac-p53/p53
ratios in wt and AD ageing mice.
Statistical significance compared
to age-matched mice is indicated
with B§^ mark (§p < 0.05;
§§p < 0.01; §§§p < 0.001)
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with animal ageing, and SLAB51 treatment partially re-
established enzyme functionality (Fig. 1a). This evidence
was in line with the parallel changes in SIRT1 expression
(SLAB51 treatment significantly counteracted the dramatic
decrease in SIRT1 levels in 18- and 24 week-old AD mice)
(Fig. 1b). Conversely, SIRT1 activity did not change at any
Fig. 3 Effect of SLAB51 on RARβ. Acetylated RARβ (a) and RARβ
(b) levels measured in brain homogenates of SLAB51-treated and
SLAB51-untreated wt (left) and AD (right) mice. The densitometric anal-
yses obtained from five separate blots and representative immunoblots are
shown. Equal protein loading was verified by using an anti-GAPDH
antibody. The detection was performed with an ECL Western blotting
analysis system. Statistical significance compared to untreated 8-week-
old mice and age-matched mice is indicated with asterisks (*p < 0.05;
**p < 0.01; ***p < 0.001) and hashtags (#p < 0.05; ##p < 0.01;
###p < 0.001), respectively. c: Pairwise comparison of the effects of
SLAB51 in Ac-RARβ/RARβ in wt and AD ageing mice. Statistical
significance compared to age-matched mice is indicated with B§^ mark
(§p < 0.05; §§p < 0.01; §§§p < 0.001)
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time point in both control and age-matched treated wt mice
(Fig. 1a, left box).
The recovery of SIRT1 functionality was also evaluated by
monitoring the levels of two protein substrates, namely RARβ
and p53, both in the acetylated and non-acetylated forms
(Fig. 2 and Fig. 3). p53 is one of the targets of SIRT1 and,
upon deacetylation, it is negatively controlled repressing the
p53-dependent apoptosis [40], whereas RARβ promotes the
non-amyloidogenic pathway for APP processing, and its acti-
vation due to deacetylation favours the transcription of
ADAM10, which encodes for α-secretase [23]. In AD mice,
SLAB51 promoted the decrease in acetylated-p53 levels al-
ready detectable in 12-week-old animals (Fig. 2, right boxes).
Additionally, probiotic administration exerted an interesting
effect on total p53, whose levels decreased in 18- and 24-
week-old AD mice. Control and age-matched treated wt mice
did not show any variations in both p53 and acetyl-p53 levels
(Fig. 2, left boxes). Acetylated RARβ levels increased time-
dependently and RARβ decreased in untreated ADmice at 18
and 24weeks of age compared to control (Fig. 3, right panels).
Fig. 4 Effect of SLAB51 on the
activity of antioxidant enzymes.
GST (a), GPx (b), SOD (c) and
CAT (d) activities measured in
brain homogenates of SLAB51-
treated and SLAB51-untreated wt
(left) and AD (right) mice (see
BMaterials and Methods^ section
for further details). Results are
expressed as fluorescence units
(F.U.). Statistical significance
compared to untreated 8-week-
old mice and age-matched mice is
indicated with asterisks
(*p < 0.05; **p < 0.01; ***p <
0.001) and hashtags (#p < 0.05;
##p < 0.01; ###p < 0.001),
respectively
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In good agreement with data on SIRT1 activity/expression,
the progressive increase in Ac-RARβ level and the
concomitant decrease in RARβ in untreated AD mice of 18
and 24 weeks were significantly counteracted by SLAB51
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treatment, which restored the 8-week-old AD mice ratio be-
tween acetylated and non-acetylated forms (Fig. 2c). SIRT1
differently affected the balance between Ac-p53 and p53, with
significant beneficial effects being observed only at the earli-
est stage of treatment (Fig. 3c).
Effect of SLAB51 Mixture on Antioxidant Enzymes
GST, GPx, SOD and CAT activities were measured in brain
homogenates from both wt and transgenic animals. Redox
enzyme activities were constant at all time points in wt mice,
regardless of the treatment with SLAB51 (Fig. 4, left insets).
Only a minor, still significant decrease was observed at
24 weeks of age in GST activity of treated wt mice (Supp.
Fig. 2, right panel). The treatment with SLAB51 significantly
modified the activity profile of these redox enzymes in AD
mice.
Generally, SLAB51 significantly affected the activity of
redox enzymes in AD mice at intermediate-to-late time points
(Supp. Fig. 3). More specifically, in untreated AD mice, GST
activity did not significantly change in ageing animals, and
SLAB51 treatment induced a substantial increase with time at
12 and 18 weeks of age. No significant change was induced in
24-week-old AD mice (Fig. 4a).
SLAB51 treatment counteracted the observed age-
dependent decrease in GPx activity with ageing at all
time points (Fig. 4b). Interestingly, the impaired enzy-
matic functionalities were associated with a time-
dependent increased expression of these enzymes in
AD subjects (data not shown).
In untreated AD mice, SOD activity significantly de-
c reased in age ing an imals more ev iden t ly a t
intermediate-to-late time points, and SLAB51 treatment
partially helped recovery basal levels of 8-week-old un-
treated AD mice. (Fig. 4c). Again, catalase activity de-
creased with time in untreated AD mice starting from
18 weeks of age, and only long-term treatment with
SLAB51 was effective in restoring basal activity of 8-
week-old untreated AD mice (Fig. 4d).
Interestingly, the effects observed on SOD and GPx
activities in untreated AD animals were in line with the
significantly compromised activity/expression of
SIRT1 at 18 and 24 weeks of age. Analogously, the
observed recovery in the activity of these redox en-
zymes upon probiotic administration could be compati-
ble with the partially restored activity/expression of
SIRT1 (Supplementary Figs. 4 and 5).
Globally, the increased activity of these enzymes upon
SLAB51 administration demonstrated the beneficial antioxi-
dant effects exerted by the probiotic formulation in AD mice
brains.
Effect of SLAB51 Mixture on Protein and Lipid
Oxidation
The effect of SLAB51 on the levels of carbonyl groups, 3-NT
and HNE-adducts (all established markers of protein and lipid
oxidation), confirmed the strong antioxidant potential of the
probiotic formulation. No change with time or treatment was
observed in the levels of protein/lipid oxidation markers here
considered in wt mice (Fig. 5, left insets). Generally, car-
bonyls, 3-NT and 4-HNE levels increased with ageing in un-
treated AD mice. SLAB51 administration effectively restored
basal levels of carbonyls and 4-HNE at all time points (Fig. 5a,
c), whereas it was less effective on 3-NT, which was signifi-
cantly decreased only at 18 and (partially) at 24 weeks of age
(Fig. 5b).
Effect of SLAB51 Mixture on DNA Oxidation and DNA
Repair Mechanisms
Minor changes were observed in wt mice in the markers
of DNA oxidative damage with time (PARP, 18-week-old
mice) and treatment (OGG1, 12-week-old mice; PARP,
24 weeks old) (Fig. 6, left insets). PARP and OGG1
are differently involved in DNA repair mechanisms:
PARP mediates DNA breaks repair, whereas OGG1
removes 8-oxoguanine base lesions generated by ROS.
Interestingly, a direct binding between OGG1 and
PARP1, enhanced by oxidative stress, was recently evi-
denced [41]. In untreated AD mice, cleaved PARP levels
increased at 18 and 24 weeks of age, and SLAB51 treat-
ment only partially (but significantly) restored initial
conditions (Fig. 6a).
Similarly, OGG1 levels increased at 18 and 24 weeks of
age in untreated AD mice, but in this case SLAB51 was ex-
tremely effective in restoring basal levels of 8-week-old un-
treated AD mice (at 12 weeks, SLAB51 decreased OGG1
levels below basal levels of 8-week-old untreated AD mice)
(Fig. 6b).
R Fig. 5 Effect of SLAB51 on protein and lipid oxidation. Protein
carbonyls (a), 3-NT (b) and 4-HNE adduct (c) levels measured in brain
homogenates of SLAB51-treated and SLAB51-untreated wt (left) and
AD (right) mice. The densitometric analyses obtained from five separate
blots and representative immunoblots are shown. Equal protein loading
for 3-NT (b) and 4-HNE adducts (c) was verified by using an anti-
GAPDH antibody. Ponceau staining has been used to check loading in
oxyblot, as reported in the BMaterials and Methods^ section (a, staining
not shown). The detection was performed with an ECLWestern blotting
analysis system. Molecular weight standards (6–205 kDa) were used for
molar mass calibration (myosin 205 kDa,β-galactosidase 116 kDa, phos-
phorylase b 97 kDa, fructose-6-phosphate kinase 80 kDa, albumin
66 kDa, glutamic dehydrogenase 55 kDa, ovalbumin 45 kDa, carbonic
anhydrase 30 kDa, trypsin inhibitor 21 kDa, lysozyme 14 kDa, aprotinin
6.5 kDa). Statistical significance compared to untreated 8-week-old mice
and age-matched mice is indicated with asterisks (*p < 0.05; **p < 0.01;
***p < 0.001) and hashtags (#p < 0.05; ##p < 0.01; ###p < 0.001),
respectively
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8-oxodg levels reached the maximum increase yet at
12weeks of age in untreated ADmice, and SLAB51 treatment
successfully restored basal levels of 8-week-old untreated AD
mice only at the earliest time point (Fig. 6c).
Discussion
Growing evidence supports the use of probiotics for the
rational manipulation of gut microbiota by virtue of
their positive influence on CNS-associated disorders
and func t ions [25 , 27 , 42 ] . In fac t , a s t r i c t
relationship/communication exists between the gastroin-
testinal tract and the brain, the so-called gut-brain axis,
which is mediated by different pathways that include
hormonal, neural and immune stimuli [43].
We have recently shown that the modulation of gut micro-
biota by using SLAB51 formulation (a mixture of lactic acid
bacteria and bifidobacteria) affects numerous neuronal path-
ways, with a significant delay of AD progression in 3xTg-AD
mice [28]. In details, SLAB51 changed microbiota composi-
tion and metabolites, favouring the proliferation of anti-
Fig. 6 Effect of SLAB51 on DNA oxidation and repair mechanisms.
Cleaved PARP (a), OGG1 (b) and 8-oxodG (c) levels measured in brain
homogenates of SLAB51-treated and SLAB51-untreated wt (left) and
AD (right) mice. The densitometric analyses obtained from five separate
blots and representative immunoblots are shown. Equal protein loading
was verified by using an anti-GAPDH antibody. The detection was per-
formed with an ECLWestern blotting analysis system. Statistical signif-
icance compared to untreated 8-week-old mice and age-matched mice is
indicated with asterisks (*p < 0.05; **p < 0.01; ***p < 0.001) and
hashtags (#p < 0.05; ##p < 0.01; ###p < 0.001), respectively
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inflammatory species and positively interfering with the con-
centration of gut hormones and peptides extremely important
in regulating energy homeostasis and food intake, and was
able to affect the CNS modulating nervous functions
[44–49]. The downstream effects of these changes included
the modulation of neuronal proteolysis, the reduction of Aβ
load and the improvement of cognitive functions, suggesting a
role for probiotics in the prevention of AD and their possible
application in AD preventative therapy [28].
The present study was conceived to explore the ability of
SLAB51 to counteract oxidative stress, a condition that is
exacerbated in the brain of AD subjects, in 3xTg-AD mice,
investigating the molecular mechanisms involved. We first
focused the attention on the role of SIRT1, a deacetylase with
a strong neuroprotective and antioxidant potential that regu-
lates the expression of several antioxidant genes, including
SOD, CAT and peroxiredoxins 3 and 5 [21, 50–57]. In the
brain of untreated AD mice, we observed a great, age-
dependent loss of SIRT1 functionality and expression levels
that negatively mediates a series of processes related to cell
survival and metabolism. In fact, the deleterious effects of
decreased SIRT1 expression are widely recognized, including
the accumulation of Aβ and tau in the cerebral cortex of pa-
tients with AD [58]. Our data demonstrate that both SIRT1
activity and expression were significantly increased in the
brain of AD mice administered with the probiotic formulation
SLAB51. The activation of SIRT1 was also confirmed by the
data on the acetylation levels of its substrate RARβ. In fact, if
an age-dependent increase in the degree of acetylation was
detected in untreated AD mice, in line with the diminished
expression of SIRT1, SLAB51 strongly reduced the amount
of RARβ acetylated lysines by restoring SIRT1 levels.
Interestingly, the deacetylation and the consequent activation
of RARβ stimulate ADAM10 gene transcription stimulating
the non-amyloidogenic pathway of APP processing and
preventing Aβ peptide generation and deposition [23, 59].
These data are in accordance with our previous studies
reporting diminished deposition of Aβ toxic fragments in
the brain of AD mice treated with SLAB51 [28].
SIRT1 activity also regulates p53 acetylation [60, 61]. p53
is stabilized upon acetylation, thus enhancing its apoptotic
activity. It has been shown that the activation of SIRT1 by
resveratrol reduced acetylation of p53 at lysine 382 and down-
regulated p53 [20]. Additionally, human SIRT1 can directly
bind p53 both in vitro and in vivo and promotes cell survival
under stress by specifically repressing p53-dependent apopto-
tic response [62]. In AD mice treated with the probiotic mix-
ture, increased levels of SIRT1 inversely correlated with acet-
ylated p53, suggesting the protective action of SLAB51
against p53-mediated apoptosis. In line with previously pub-
lished data on the level of p53 in AD brain, we observed
higher level of the protein in the brain of untreated AD mice
[63, 64]. These elevated p53 levels were proposed to favour
tau phosphorylation in HEK293a cells [63]. p53 behaviour is
in agreement with our previous findings on UPS functionality;
being p53 is a well-known proteasome substrate, it is reason-
able that it accumulates in AD mice with impaired UPS-
mediated proteolysis, and that SLAB51 administration results
in decreased levels of proteasome substrates (among these
p53), due to restored proteasome activities [28]. Moreover,
p53 deacetylation by activated SIRT1 is also related to ghrelin
increased plasma levels in the same AD mouse model upon
SLAB51 oral administration, as we have previously shown
[28]. In fact, ghrelin has been demonstrated to promote the
hypothalamic SIRT1-p53 pathway, causing changes in fatty
acids metabolism and feeding behaviour [65]. These data are
in agreement with our previous work reporting an enriched
gut concentration of anti-inflammatory short chain fatty acids
and a decrease of pro-inflammatory cytokine levels in
SLAB51-treated AD mice [28]. Collectively, these data
strongly support the idea that SLAB51 activates SIRT1 path-
way, this latter representing a link between metabolism and
inflammation [66]. In fact, inhibition of SIRT1 activity by
oxidative stress reduces its levels by posttranslational modifi-
cations, favouring its nucleocytoplasmic shuttling and deter-
mining the accumulation of transcription factors and modifi-
cations of histones H3 and H4. These events finally cause the
abnormal transcription of pro-inflammatory, prosenescent and
proapoptotic mediators [67].
Being SIRT1 directly involved in the regulation of the ox-
idative stress, whose levels were demonstrated to be extremely
high in the brain of AD subjects [68, 69], we measured the
functionality of redox enzymes and the amount of well-
established markers of proteins, lipid and DNA oxidation to
evaluate if the SLAB51-induced activation of SIRT1 pathway
effectively corresponded to an antioxidant action. We ob-
served severe age-dependent alterations of the oxidative status
in the brains of AD transgenic mice. Compared to the 8-week-
old animals, elder AD individuals showed decreased activities
of antioxidant enzymes, mainly GPx and catalase, despite of
the increased expression levels of such enzymes. These data
are in agreement with other authors’ evidence that describes a
Bredistribution phenomenon,^ with the enzymes being more
concentrated in the oxidized sites but dramatically impaired in
their functionality [70]. Simultaneously, an intense enhance-
ment of macromolecule oxidation markers, including car-
bonyls, 3-NT, 4-HNE and 8-oxodG, was detected in AD
brains. Interestingly, in AD mice SLAB51 administration
markedly mitigated oxidative stress-related damages as indi-
cated by the evident increase in the activity of antioxidant
enzymes and the diminished levels of macromolecule oxida-
tion markers.
Finally, PARP cleavage and OGG1 levels increased in AD-
untreated mice in response to the accumulation of oxidized
species of DNA [71]. This result is in agreement with the
suppression of SIRT1 expression in the same mice. In fact,
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PARP and SIRT1 share NAD+ as cofactor [72], thus PARP1
activation can inhibit SIRT1 functionality [73].
Collectively, these data demonstrated the great impact of
SIRT1 pathway reactivation upon SLAB51 administration in
preserving brain redox homeostasis, with positive outcomes
for AD. This property makes SLAB51 able to act at different
levels in the cell, by exerting beneficial effects that definitely
ameliorate the symptomatology of AD. These findings further
contribute to unveil the innovative role for microbiota manip-
ulative strategies for future AD (co)therapies involving probi-
otic approaches.
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